These findings implied that LCN2′s anti-metastatic actions in human osteosarcoma HOS and U2OS cells resulted from attenuation of the MET expression and activity through the MEK–ERK pathway rather than JNK and p38 signaling. This evidence concerns the gene LCN2 and osteosarcoma.